Acute myeloid leukaemia vaccine - GSK
Alternative Names: 2130579A; GSK 2130579A; WT1-A10+AS01B ASCILatest Information Update: 05 Nov 2023
At a glance
- Originator Corixa Corp
- Developer GSK
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 01 Jun 2016 GlaxoSmithKline completes a phase I trial for Acute myeloid leukaemia in USA and France (NCT00725283)
- 01 Apr 2016 GlaxoSmithKline completes a phase I trial in Acute myeloid leukaemia in USA, France and Germany (IM) (NCT01051063)
- 20 Apr 2012 GlaxoSmithKline completes enrolment in its phase I trial for Acute myeloid leukaemia in USA and France (NCT00725283)